摘要
目的:建立ActRⅡB-Fc融合蛋白的生物学活性检测方法。方法:利用A204-CAGA12-LUC细胞系,通过荧光素酶检测系统进行ActRⅡB-Fc融合蛋白的生物学活性检测,根据四参数拟合分析计算样品相对效价,并对该方法的专属性、精密性和准确性进行验证。结果:ActRⅡB-Fc融合蛋白在该方法中存在量效关系,且符合4-参数方程:y=(A-D)/[1+(x/C)^(B)]+D。该方法具有良好的专属性;6批ActRⅡB-Fc融合蛋白样品经3次测定,相对效价平均值在(86.74±6.44)%~(108.81±15.07)%,RSD均小于15%;2批回收率样品经3次测定,回收率分别为(114.99±12.42)%和(81.19±7.35)%;8次独立测定重复性较好。结论:研究建立的ActRⅡB-Fc融合蛋白生物学活性检测方法专属性强,准确性高,精密度好,可作为ActRⅡB-Fc融合蛋白生物学活性的常规检测方法。
Objective:To establish a method to detect the biological activity of ActRⅡB-Fc fusion protein.Methods:The biological activity of ActRⅡB-Fc fusion protein was determined by ONE-Glo;Luciferase Assay System with the use of A204-CAGA12-LUC cell line,and the relative potency of the samples was calculated by four-parameter fitting analysis.The developed method was validated in specification,precision and accuracy.Results:ActRⅡB-Fc fusion protein shows a dose-effect ralationship in this method and it was in accordance with the four-parameter equation:y=(A-D)/[1+(x/C)^(B)]+D.The method has good specificity.Six batches of samples of the ActRⅡB-Fc fusion protein were tested for 3 times,and the average relative potencies ranged from(86.74±6.44)%to(108.81±15.07)%with relative standard deviation less than 15%.Two batches of recovery samples were detected for 3 times,the recoveries of which were(114.99±12.42)%and(81.19±7.35)%respectively.The results of 8 independent determinations showed good reproducibility.Conclusion:A method for detecting biological activity of ActRⅡB-Fc fusion protein has been successfully developed,which shows good specification,precision and accuracy and can be used as a routine method for biological activity detection of ActRⅡB-Fc fusion protein.
作者
刘春雨
于传飞
李欣
崔永霏
武刚
王兰
Liu Chunyu;Yu Chuanfei;Li Xin;Cui Yongfei;Wu Gang;Wang Lan(Monoclonal Anti-body Product Office of National Institutes for Food and Drug Control,NHC Key Laboratory of Research on Determination Method and Standardization of Biotech Products,NMPA Key Laboratory for Quality Research and Evaluation of Biological Products,Beijing 102629,China;Guangzhou Insititue for Drug Control,Guangzhou 510160,China)
出处
《中国药事》
CAS
2022年第3期293-300,共8页
Chinese Pharmaceutical Affairs
基金
国家“重大新药创制”科技重大专项(编号2018ZX09736008-006)
中山市重大科技专项(编号210204163866513)。